Physician profile
Ethan Binder
NPI 1598028540
$15,759.43
in general payments reported to CMS, 2019-2025
42 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $256 · 2021: $15.49 · 2022: $11K · 2023: $633 · 2024: $1,729 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,069 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,069.08 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $11,476.58 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $579.39 | 2019-2025 | |
| Pfizer INC. | $347.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $245.11 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $244.71 | 2019-2024 | Darzalex, Tecvayli, Erleada |
| Astellas Pharma US INC | $240.90 | 2019-2025 | Xtandi |
| Gilead Sciences, INC. | $235.08 | 2023-2025 | Trodelvy |
| Seagen INC. | $220.30 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Astrazeneca Pharmaceuticals LP | $198.30 | 2020-2025 | Tagrisso, Enhertu, Lynparza |
| Abbvie INC. | $195.63 | 2024-2025 | |
| Incyte Corporation | $155.87 | 2020-2025 | Monjuvi, Zynyz, Jakafi |
| Kite Pharma, INC. | $126.45 | 2020-2025 | Yescarta |
| Genentech USA, INC. | $114.79 | 2019-2024 | Phesgo, Perjeta, Itovebi |
| Merck Sharp & Dohme LLC | $113.08 | 2019-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $103.30 | 2023-2025 | Ojjaara, Jemperli, Zejula |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Binder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.